Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Gross Profit: 2009-2025

Historic Gross Profit for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $3.9 million.

  • Cumberland Pharmaceuticals' Gross Profit fell 17.70% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 25.70%. This contributed to the annual value of $20.8 million for FY2024, which is 1.21% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Gross Profit stood at $3.9 million, which was down 41.66% from $6.6 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Gross Profit ranged from a high of $7.5 million in Q1 2025 and a low of $3.9 million during Q3 2025.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Gross Profit value was $5.3 million (recorded in 2023), while the average stood at $5.4 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Gross Profit dropped by 26.84% in 2023, and later skyrocketed by 72.25% in 2025.
  • Cumberland Pharmaceuticals' Gross Profit (Quarterly) stood at $5.0 million in 2021, then climbed by 14.57% to $5.7 million in 2022, then declined by 20.03% to $4.6 million in 2023, then soared by 35.25% to $6.2 million in 2024, then decreased by 17.70% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $6.6 million for Q2 2025, and $7.5 million during Q1 2025.